HC Wainwright & Co. Upholds Neutral Rating for Cytosorbents (CTSO)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 15 2025
0mins
Source: NASDAQ.COM
Analyst Recommendation: HC Wainwright & Co. maintains a Neutral recommendation for Cytosorbents (NasdaqCM:CTSO) as of November 14, 2025, with a projected one-year price target of $5.10/share, indicating a potential upside of 672.73% from its current price of $0.66/share.
Projected Revenue and EPS: Cytosorbents is expected to see a significant increase in annual revenue, projected at $122 million, which represents a 237.10% growth, alongside a projected non-GAAP EPS of 0.17.
Fund Sentiment: There are currently 73 funds reporting positions in Cytosorbents, reflecting an 8.96% increase in ownership over the last quarter, with total institutional shares rising by 1.15% to 18,005K shares.
Shareholder Activity: Notable changes in shareholder allocations include Avenir increasing its stake slightly, while Skylands Capital and Neuberger Berman Group both reduced their holdings significantly over the last quarter.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CTSO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CTSO
Wall Street analysts forecast CTSO stock price to rise
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 0.391
Low
0.75
Averages
0.75
High
0.75
Current: 0.391
Low
0.75
Averages
0.75
High
0.75
About CTSO
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Virtual Investor Conferences Forum Highlights
- On-Demand Presentations: The Life Sciences Virtual Investor Forum held on June 24-25, 2026, is now available for on-demand viewing for 90 days, enhancing investor engagement and understanding of participating companies.
- Company Participation: Companies such as MetaVia Inc. (NASDAQ: MTVA) and CytoSorbents Corporation (NASDAQ: CTSO) are accepting one-on-one management meeting requests, facilitating direct communication between investors and management teams.
- Investor Materials Access: Attendees can download investor materials from the companies' resource sections, which not only increases transparency but also provides potential investors with essential decision-making support.
- Interactive Platform Benefits: Virtual Investor Conferences offer real-time investor engagement solutions that replicate the components of on-site conferences, improving the efficiency of connections between companies and investors, thereby fostering stronger investor relations.
See More
Agenda Announced for Life Sciences Virtual Investor Forum
- Forum Schedule: The Life Sciences Virtual Investor Forum, taking place on June 24-25, 2026, will bring together innovators from various companies, providing an efficient platform for direct engagement between investors and companies, expected to attract numerous individual and institutional investors.
- Easy Participation: Investors can register for free and run an online system check to expedite participation and receive event updates, with live company presentations and one-on-one meeting arrangements enhancing the investor experience during the forum.
- Company Showcase: The forum will feature multiple publicly traded companies, including MetaVia Inc. and CytoSorbents Corporation, covering various life sciences sectors, which is expected to provide investors with rich industry insights and investment opportunities.
- Investor Relations Enhancement: Virtual Investor Conferences aim to improve communication efficiency between companies and investors by offering real-time interactive engagement solutions, helping companies better showcase their strategies and business development plans.
See More
Cytosorbents Q1 2026 Earnings Call Insights
- Revenue Growth: Cytosorbents reported a 2% year-over-year revenue increase to $8.9 million in Q1 2026, demonstrating resilience in international markets, particularly with a 13% growth outside Germany despite external challenges.
- Cost Control: Operating expenses decreased to $9.2 million from $10.1 million a year ago, reflecting initial benefits from the strategic headcount and cost reduction program implemented in Q4, with expectations for continued cost reductions.
- Regulatory Delay: The FDA's request for additional mechanistic data may delay the new de novo application for DrugSorb-ATR until late 2026 or early 2027, potentially impacting the company's expansion plans in the U.S. market.
- Market Opportunity: The potential market size for DrugSorb-ATR could reach $500 million to $1 billion if approvals for both Brilinta and DOAC removal are granted, significantly expanding the company's market share, although geopolitical risks from the Middle East pose challenges.
See More
Cytosorbents Q1 Earnings Report Analysis
- Earnings Highlights: Cytosorbents reported a non-GAAP EPS of $0.05 for Q1, indicating a slight year-over-year improvement, yet it falls short of expectations, highlighting ongoing challenges in profitability.
- Revenue Performance: The company generated $8.9 million in revenue for the first quarter, marking a 1.9% year-over-year increase, but it missed market expectations by $460,000, reflecting sluggish sales growth.
- Future Outlook: Cytosorbents aims to achieve cash flow breakeven in the second half of 2026, indicating a strategic pivot to navigate the current market landscape and enhance international sales growth.
- Market Reaction: Despite efforts to expand in international markets, the current financial performance has failed to instill investor confidence, potentially exerting negative pressure on the stock price and reflecting market caution regarding the company's future prospects.
See More
Cytosorbents to Announce Q1 Earnings on May 13
- Earnings Announcement Date: Cytosorbents (CTSO) is set to release its Q1 2023 earnings report on May 13 after market close, with a consensus EPS estimate of -$0.06, indicating ongoing challenges in profitability.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $9.36 million, reflecting a 7.2% year-over-year increase, suggesting that despite profitability pressures, the company is achieving steady revenue growth amid international sales expansion.
- Historical Performance Review: Over the past two years, Cytosorbents has only beaten EPS estimates 13% of the time and revenue estimates 50% of the time, highlighting uncertainty in financial performance that may affect investor confidence.
- Future Outlook: Cytosorbents has outlined a path to cash flow breakeven by the second half of 2026, indicating strategic planning for international market expansion aimed at improving long-term financial health.
See More
CytoSorbents Reports 4% Revenue Growth in 2025
- Annual Revenue Growth: CytoSorbents achieved a full-year revenue of $37.1 million in 2025, reflecting a 4% increase year-over-year, primarily driven by strong performance in international markets, indicating the company's potential for global expansion.
- Gross Margin Performance: The company reported a gross margin of 71% for the full year and 74% in Q4, showcasing improved manufacturing efficiencies that enhance profitability in the competitive medical device sector.
- Challenges in Germany: Sales in Germany declined by 10% to $11.8 million, reflecting the near-term impact of restructuring efforts, although the company is implementing strategies to improve market performance and restore growth.
- Cost Structure Optimization: Operating expenses remained flat at $41.2 million, yet through cost reductions and a strengthened balance sheet, the company aims to achieve cash flow breakeven in the second half of 2026, demonstrating potential for sustainable growth.
See More
Virtual Investor Conferences Forum Highlights
- On-Demand Presentations: The Life Sciences Virtual Investor Forum held on June 24-25, 2026, is now available for on-demand viewing for 90 days, enhancing investor engagement and understanding of participating companies.
- Company Participation: Companies such as MetaVia Inc. (NASDAQ: MTVA) and CytoSorbents Corporation (NASDAQ: CTSO) are accepting one-on-one management meeting requests, facilitating direct communication between investors and management teams.
- Investor Materials Access: Attendees can download investor materials from the companies' resource sections, which not only increases transparency but also provides potential investors with essential decision-making support.
- Interactive Platform Benefits: Virtual Investor Conferences offer real-time investor engagement solutions that replicate the components of on-site conferences, improving the efficiency of connections between companies and investors, thereby fostering stronger investor relations.
See More
Agenda Announced for Life Sciences Virtual Investor Forum
- Forum Schedule: The Life Sciences Virtual Investor Forum, taking place on June 24-25, 2026, will bring together innovators from various companies, providing an efficient platform for direct engagement between investors and companies, expected to attract numerous individual and institutional investors.
- Easy Participation: Investors can register for free and run an online system check to expedite participation and receive event updates, with live company presentations and one-on-one meeting arrangements enhancing the investor experience during the forum.
- Company Showcase: The forum will feature multiple publicly traded companies, including MetaVia Inc. and CytoSorbents Corporation, covering various life sciences sectors, which is expected to provide investors with rich industry insights and investment opportunities.
- Investor Relations Enhancement: Virtual Investor Conferences aim to improve communication efficiency between companies and investors by offering real-time interactive engagement solutions, helping companies better showcase their strategies and business development plans.
See More
Cytosorbents Q1 2026 Earnings Call Insights
- Revenue Growth: Cytosorbents reported a 2% year-over-year revenue increase to $8.9 million in Q1 2026, demonstrating resilience in international markets, particularly with a 13% growth outside Germany despite external challenges.
- Cost Control: Operating expenses decreased to $9.2 million from $10.1 million a year ago, reflecting initial benefits from the strategic headcount and cost reduction program implemented in Q4, with expectations for continued cost reductions.
- Regulatory Delay: The FDA's request for additional mechanistic data may delay the new de novo application for DrugSorb-ATR until late 2026 or early 2027, potentially impacting the company's expansion plans in the U.S. market.
- Market Opportunity: The potential market size for DrugSorb-ATR could reach $500 million to $1 billion if approvals for both Brilinta and DOAC removal are granted, significantly expanding the company's market share, although geopolitical risks from the Middle East pose challenges.
See More
Cytosorbents Q1 Earnings Report Analysis
- Earnings Highlights: Cytosorbents reported a non-GAAP EPS of $0.05 for Q1, indicating a slight year-over-year improvement, yet it falls short of expectations, highlighting ongoing challenges in profitability.
- Revenue Performance: The company generated $8.9 million in revenue for the first quarter, marking a 1.9% year-over-year increase, but it missed market expectations by $460,000, reflecting sluggish sales growth.
- Future Outlook: Cytosorbents aims to achieve cash flow breakeven in the second half of 2026, indicating a strategic pivot to navigate the current market landscape and enhance international sales growth.
- Market Reaction: Despite efforts to expand in international markets, the current financial performance has failed to instill investor confidence, potentially exerting negative pressure on the stock price and reflecting market caution regarding the company's future prospects.
See More
Cytosorbents to Announce Q1 Earnings on May 13
- Earnings Announcement Date: Cytosorbents (CTSO) is set to release its Q1 2023 earnings report on May 13 after market close, with a consensus EPS estimate of -$0.06, indicating ongoing challenges in profitability.
- Revenue Growth Expectations: The anticipated revenue for Q1 is $9.36 million, reflecting a 7.2% year-over-year increase, suggesting that despite profitability pressures, the company is achieving steady revenue growth amid international sales expansion.
- Historical Performance Review: Over the past two years, Cytosorbents has only beaten EPS estimates 13% of the time and revenue estimates 50% of the time, highlighting uncertainty in financial performance that may affect investor confidence.
- Future Outlook: Cytosorbents has outlined a path to cash flow breakeven by the second half of 2026, indicating strategic planning for international market expansion aimed at improving long-term financial health.
See More
CytoSorbents Reports 4% Revenue Growth in 2025
- Annual Revenue Growth: CytoSorbents achieved a full-year revenue of $37.1 million in 2025, reflecting a 4% increase year-over-year, primarily driven by strong performance in international markets, indicating the company's potential for global expansion.
- Gross Margin Performance: The company reported a gross margin of 71% for the full year and 74% in Q4, showcasing improved manufacturing efficiencies that enhance profitability in the competitive medical device sector.
- Challenges in Germany: Sales in Germany declined by 10% to $11.8 million, reflecting the near-term impact of restructuring efforts, although the company is implementing strategies to improve market performance and restore growth.
- Cost Structure Optimization: Operating expenses remained flat at $41.2 million, yet through cost reductions and a strengthened balance sheet, the company aims to achieve cash flow breakeven in the second half of 2026, demonstrating potential for sustainable growth.
See More
